Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jaut.2022.102959
Title: Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Authors: Ma, Margaret
Santosa, Amelia
Kong, Kok Ooi
Xu, Chuanhui
Teng, Gim Gee 
Tang, Johnston GX
Mak, Anselm 
Tay, Frank
Ng, Victoria WW
Koh, Joshua ZE
Fong, Warren 
Chew, Li-Ching 
Low, Andrea 
Law, Annie 
Poh, Yih Jia
Yeo, Siaw Ing
Leung, Ying Ying 
Goh, Wei-Rui
Roslan, Nur Emilia
Chuah, Tyng Yu
Angkodjojo, Stanley
Arkachaisri, Thaschawee
Teh, Kai Liang
Phang, Kee Fong
Sriranganathan, Melonie
Tan, Teck Choon
Cheung, Peter 
Lahiri, Manjari 
Keywords: Autoimmune inflammatory rheumatic diseases
COVID vaccines
Registry
Issue Date: Sep-2022
Publisher: WILEY
Citation: Ma, Margaret, Santosa, Amelia, Kong, Kok Ooi, Xu, Chuanhui, Teng, Gim Gee, Tang, Johnston GX, Mak, Anselm, Tay, Frank, Ng, Victoria WW, Koh, Joshua ZE, Fong, Warren, Chew, Li-Ching, Low, Andrea, Law, Annie, Poh, Yih Jia, Yeo, Siaw Ing, Leung, Ying Ying, Goh, Wei-Rui, Roslan, Nur Emilia, Chuah, Tyng Yu, Angkodjojo, Stanley, Arkachaisri, Thaschawee, Teh, Kai Liang, Phang, Kee Fong, Sriranganathan, Melonie, Tan, Teck Choon, Cheung, Peter, Lahiri, Manjari (2022-09). Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING). ARTHRITIS & RHEUMATOLOGY 74 : 1577-1579. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jaut.2022.102959
Abstract: Background: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. Methods: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. Findings: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. Interpretation: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended.
Source Title: ARTHRITIS & RHEUMATOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/245589
ISSN: 2326-5191
2326-5205
DOI: 10.1016/j.jaut.2022.102959
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
CONVINSING_JAutoimmunity.pdfPublished version1.33 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.